Eprenetapopt

NSCLC

Aprea TherapeuticsSmall moleculePhase 1/2Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 36/ 100
Competitive Position: 65/ 100

Competitive context

112 Active assets in the NSCLC cohort.

Asset / Sponsor	Phase	Rating
Dacomitinib Pfizer	Phase 4	BB
Penpulimab Yang Fan, MD	Phase 4	BB
Fruquintinib Immunitas Therapeutics	Phase 3	BB
Adebrelimab Peking University Cancer Hospital & Institute	Phase 3	BB
Rezivertinib The First Affiliated Hospital of Guangzhou Medical University	Phase 3	BB

View all 50 →

Same molecule, other indications

Eprenetapopt is also rated in:

ovarian serous adenocarcinomaDormant

B

Indicative ·

62 / 100

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant

CCC

Indicative ·

54 / 100

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53Dormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.